Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial

医学 血管内超声 急性冠脉综合征 冠状动脉造影 内科学 超声波 药物洗脱支架 心脏病学 支架 药品 放射科 外科 心肌梗塞 再狭窄 精神科
作者
Zhen Ge,Xiaofei Gao,Jing Kan,Xiangquan Kong,Guang‐Feng Zuo,Fei Ye,Nai‐Liang Tian,Song Lin,Zhizhong Liu,Yibing Shao,Yuquan He,Shangyu Wen,Qing Yang,Yong Xia,Zhengzhong Wang,Pingxi Xiao,Li Feng,Hesong Zeng,Song Yang,Yan Wang
出处
期刊:American Heart Journal [Elsevier BV]
卷期号:236: 49-58 被引量:17
标识
DOI:10.1016/j.ahj.2021.02.014
摘要

Current guidelines recommend administering dual antiplatelet therapy (DAPT) for 12 months to patients with acute coronary syndromes (ACS) and without contraindications after drug-eluting stent (DES) implantation. A recent study reported that 3 months of DAPT followed by ticagrelor monotherapy is effective and safe in ACS patients undergoing DES implantation compared with the standard duration of DAPT. However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor.The IVUS-ACS and ULTIMATE-DAPT is a prospective, multicenter, randomized, controlled trial designed to determine (1) whether IVUS-guided versus angiography-guided DES implantation in patients with ACS reduces the risk of target vessel failure (TVF) at 12 months and (2) whether ticagrelor alone versus ticagrelor plus aspirin reduces the risk of clinically relevant bleeding without increasing the risk of MACCE 1-12 months after the index PCI in ACS patients undergoing DES implantation guided by either IVUS or angiography. This study will enroll 3486 ACS patients eligible for DES implantation, as confirmed by angiographic studies. The patients who meet the inclusion criteria and none of the exclusion criteria will be randomly assigned in a 1:1 fashion to the IVUS- or angiography-guided group (first randomization). All enrolled patients will complete a 1-month course of DAPT with aspirin plus ticagrelor after the index PCI. Patients with no MACCEs or major bleeding (≥Bleeding Academic Research Consortium (BARC) 3b) within 30 days will be randomized in a 1:1 fashion to either the ticagrelor plus matching placebo (SAPT)group or ticagrelor plus aspirin (DAPT)group for an additional 11 months (second randomization). The primary endpoint of the IVUS-ACS trial is TVF at 12 months, including cardiac death, target vessel myocardial infarction (TVMI), or clinically driven target vessel revascularization (CD-TVR). The primary superiority endpoint of the ULTIMATE-DAPT trial is clinically relevant bleeding, defined as BARC Types 2, 3, or 5 bleeding, and the primary non-inferiority endpoint of the ULTIMATE-DAPT trial is MACCE, defined as cardiac death, myocardial infarction, ischemic stroke, CD-TVR, or definite stent thrombosis occurring 1-12 months in the second randomized population.The IVUS-ACS and ULTIMATE-DAPT trial is designed to test the efficacy and safety of 2 different antiplatelet strategies in ACS patients undergoing PCI with DES implantation guided by either IVUS or angiography. This study will provide novel insights into the optimal DAPT duration in ACS patients undergoing PCI and provide evidence on the clinical benefits of IVUS-guided PCI in ACS patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
刚刚
Z17发布了新的文献求助10
刚刚
1秒前
hh哈哈完成签到,获得积分10
1秒前
DC-CIK军团完成签到 ,获得积分10
2秒前
2秒前
打打应助King16采纳,获得10
4秒前
5秒前
5秒前
5秒前
6秒前
8秒前
一杯奶茶完成签到,获得积分10
9秒前
9秒前
sherry完成签到,获得积分10
9秒前
karate09judges完成签到 ,获得积分10
10秒前
阿芝发布了新的文献求助10
10秒前
大海123发布了新的文献求助10
10秒前
阳佟雨南完成签到,获得积分10
11秒前
11秒前
chen发布了新的文献求助10
13秒前
katsuras发布了新的文献求助10
14秒前
Hello应助zong采纳,获得10
14秒前
凌鸣发布了新的文献求助10
14秒前
14秒前
15秒前
NexusExplorer应助继续加油吧采纳,获得10
16秒前
16秒前
eason应助大海123采纳,获得10
16秒前
17秒前
云长两里乌完成签到 ,获得积分10
17秒前
讨厌胡萝卜完成签到,获得积分10
17秒前
汉堡包应助Z17采纳,获得10
19秒前
19秒前
赫青亦完成签到 ,获得积分10
19秒前
yangyangyang发布了新的文献求助10
19秒前
hujun完成签到 ,获得积分10
19秒前
夏日风息发布了新的文献求助10
20秒前
20秒前
kxran发布了新的文献求助10
21秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
Atlas of Interventional Pain Management 300
Novel Preparation of Chitin Nanocrystals by H2SO4 and H3PO4 Hydrolysis Followed by High-Pressure Water Jet Treatments 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4011029
求助须知:如何正确求助?哪些是违规求助? 3550660
关于积分的说明 11306082
捐赠科研通 3284968
什么是DOI,文献DOI怎么找? 1810924
邀请新用户注册赠送积分活动 886594
科研通“疑难数据库(出版商)”最低求助积分说明 811526